Healthcare Contract Manufacturing Outsourcing (CMO) Market - Forecasts from 2016 to 2021
Global Healthcare Contract Manufacturing Outsourcing (CMO) Market is projected to grow at a compound annual growth rate of 10.28% over the forecast period to reach US$205.104 billion by 2021, from US$114.018 billion in 2015. Rising research and development cost of drugs is driving the healthcare CMO market. Industry and government regulations have forced enterprises to outsource manufacturing operations to the third party to remain competitive and enhance business process efficiency. Increasing investment in the healthcare sector has also provided the necessary impetus to the market. The emergence of developing economies of China and India as favorable manufacturing markets is shifting the balance towards these countries as compared to Europe, which has dominated the CMO market.
The first section of the report deals with detailed research methodology for calculating market size and forecasts, secondary data sources used and the primary inputs which were taken for data validation. This section also outlines various segmentations which have been covered as part of the report.
Next section provides comprehensive market dynamics through an overview section along with growth drivers, challenges, and opportunities which exist in the current market. This section of the report also provides supplier and industry outlook as a whole; key industry, global and regional regulations which are determining the product specifications and a brief technological aspect of Healthcare CMO solutions. Complete industry analysis has also been covered by Porter’s five forces model as a part of this report section.
Thirdly, Healthcare CMO market has been segmented on the basis of services and geography. Under different services, pharmaceutical CMO, and medical device CMO have been covered. By pharmaceutical CMO this market has been segmented into Active Pharmaceutical Ingredients (API) Manufacturing, Final Dose Formulation (FDF) Manufacturing and Packaging services, while under medical device CMO Design Outsourcing, Device Manufacturing and Final Goods Assembly have been covered through detailed market analysis and forecast for the next five years.
Important regions for vendors in terms of market size is covered through detailed geographical segmentation. Geographical regions covered as a part of this section are Americas (North and South America), Europe Middle East and Africa and Asia Pacific.
Finally, competitive intelligence section deals with major players in the market, their market shares, growth strategies, products, financials, and recent investments among others. Key industry players profiled as part of this section are Jubilant Life Sciences Limited, Pfizer CentreOne, Lonza Group, Recipharm AB, Catalent and DPx Holdings along with several other players
The first section of the report deals with detailed research methodology for calculating market size and forecasts, secondary data sources used and the primary inputs which were taken for data validation. This section also outlines various segmentations which have been covered as part of the report.
Next section provides comprehensive market dynamics through an overview section along with growth drivers, challenges, and opportunities which exist in the current market. This section of the report also provides supplier and industry outlook as a whole; key industry, global and regional regulations which are determining the product specifications and a brief technological aspect of Healthcare CMO solutions. Complete industry analysis has also been covered by Porter’s five forces model as a part of this report section.
Thirdly, Healthcare CMO market has been segmented on the basis of services and geography. Under different services, pharmaceutical CMO, and medical device CMO have been covered. By pharmaceutical CMO this market has been segmented into Active Pharmaceutical Ingredients (API) Manufacturing, Final Dose Formulation (FDF) Manufacturing and Packaging services, while under medical device CMO Design Outsourcing, Device Manufacturing and Final Goods Assembly have been covered through detailed market analysis and forecast for the next five years.
Important regions for vendors in terms of market size is covered through detailed geographical segmentation. Geographical regions covered as a part of this section are Americas (North and South America), Europe Middle East and Africa and Asia Pacific.
Finally, competitive intelligence section deals with major players in the market, their market shares, growth strategies, products, financials, and recent investments among others. Key industry players profiled as part of this section are Jubilant Life Sciences Limited, Pfizer CentreOne, Lonza Group, Recipharm AB, Catalent and DPx Holdings along with several other players
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Overview and Segmentations
4.2. Drivers
4.3. Restraints
4.4. Opportunities
4.5. Supplier Outlook
4.6. Industry Outlook
4.7. Porter’s 5 Forces Analysis
4.8. Industry Value Chain Analysis
5. HEALTHCARE CMO MARKET FORECAST BY SERVICES (US$ BILLION)
5.1. Pharmaceutical CMO
5.1.1. Active Pharmaceutical Ingredients (API) Manufacturing
5.1.2. Final Dose Formulation (FDF) Manufacturing
5.1.2.1. Injectable Dose Formulations
5.1.2.2. Solid Dose Formulations
5.1.2.3. Semi-solid Dose Formulations
5.1.2.4. Liquid Dose Formulations
5.1.3. Packaging
5.2. Medical Device CMO
5.2.1. Design Outsourcing
5.2.2. Device Manufacturing
5.2.3. Final Goods Assembly
6. HEALTHCARE CMO MARKET FORECAST BY GEOGRAPHY (US$ BILLION)
6.1. Americas
6.1.1. North America
6.1.1.1. United States
6.1.1.2. Canada
6.1.1.3. Mexico
6.1.2. South America
6.1.2.1. Brazil
6.1.2.2. Others
6.1.3. Europe Middle East and Africa
6.1.3.1. Europe
6.1.3.1.1. United Kingdom
6.1.3.1.2. Germany
6.1.3.1.3. France
6.1.3.1.4. Spain
6.1.3.1.5. Italy
6.1.3.1.6. Others
6.1.3.2. Middle East and Africa
6.1.4. Asia Pacific
6.1.4.1. China
6.1.4.2. Japan
6.1.4.3. India
6.1.4.4. Australia
6.1.4.5. Others
7. COMPETITIVE INTELLIGENCE
7.1. Market Share of Key Players
7.2. Investment Analysis
7.3. Recent Deals
7.4. Strategies of Key Players
8. COMPANY PROFILES
8.1. Jubilant Life Sciences Limited
8.2. Pfizer CentreOne
8.3. Lonza Group
8.4. BIOMEVA
8.5. Recipharm AB
8.6. Catalent
8.7. The Aenova Group
8.8. Baxter
8.9. Boehringer Ingelheim
8.10. DPx Holdings
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Overview and Segmentations
4.2. Drivers
4.3. Restraints
4.4. Opportunities
4.5. Supplier Outlook
4.6. Industry Outlook
4.7. Porter’s 5 Forces Analysis
4.8. Industry Value Chain Analysis
5. HEALTHCARE CMO MARKET FORECAST BY SERVICES (US$ BILLION)
5.1. Pharmaceutical CMO
5.1.1. Active Pharmaceutical Ingredients (API) Manufacturing
5.1.2. Final Dose Formulation (FDF) Manufacturing
5.1.2.1. Injectable Dose Formulations
5.1.2.2. Solid Dose Formulations
5.1.2.3. Semi-solid Dose Formulations
5.1.2.4. Liquid Dose Formulations
5.1.3. Packaging
5.2. Medical Device CMO
5.2.1. Design Outsourcing
5.2.2. Device Manufacturing
5.2.3. Final Goods Assembly
6. HEALTHCARE CMO MARKET FORECAST BY GEOGRAPHY (US$ BILLION)
6.1. Americas
6.1.1. North America
6.1.1.1. United States
6.1.1.2. Canada
6.1.1.3. Mexico
6.1.2. South America
6.1.2.1. Brazil
6.1.2.2. Others
6.1.3. Europe Middle East and Africa
6.1.3.1. Europe
6.1.3.1.1. United Kingdom
6.1.3.1.2. Germany
6.1.3.1.3. France
6.1.3.1.4. Spain
6.1.3.1.5. Italy
6.1.3.1.6. Others
6.1.3.2. Middle East and Africa
6.1.4. Asia Pacific
6.1.4.1. China
6.1.4.2. Japan
6.1.4.3. India
6.1.4.4. Australia
6.1.4.5. Others
7. COMPETITIVE INTELLIGENCE
7.1. Market Share of Key Players
7.2. Investment Analysis
7.3. Recent Deals
7.4. Strategies of Key Players
8. COMPANY PROFILES
8.1. Jubilant Life Sciences Limited
8.2. Pfizer CentreOne
8.3. Lonza Group
8.4. BIOMEVA
8.5. Recipharm AB
8.6. Catalent
8.7. The Aenova Group
8.8. Baxter
8.9. Boehringer Ingelheim
8.10. DPx Holdings
